Omega-3 Fatty Acid Supplements and Dry Eye

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Omega-3 fatty acids have been associated with a decline in inflammation. As dry eye disease is associated with inflammation of the ocular surface (DEWS report, Ocular Surface, 2007), the investigators hypothesize that the omega-3 fatty acid supplements used in this study will help to improve dry eye signs, such as eye surface irritation (staining) and tear film osmolarity, which is an overall measure of tear film stability and dry eye status. Further, the investigators hypothesize that dry eye symptoms, the end result of dry eye disease, such as discomfort and burning, will also improve with supplementation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Omega-3 Fatty Acid Supplementation and Tear Film Quality in Celiac Patients

NCT05825976

Dry Eye Syndromes Celiac Disease

UNKNOWN NA

Fish Oil (Omega 3), Immune Function, and Mood

NCT00385723

Inflammation

COMPLETED PHASE2

Omega-3 Fatty Acids for Treatment of Depression in Adolescents

NCT00658476

Depression

COMPLETED PHASE3

Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

NCT02486042

Retinopathy of Prematurity

COMPLETED PHASE2

DHA Supplementation in Patients With STGD3

NCT00420602

Dominantly Inherited Stargardt's Disease (STGD3)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dry Eye is a disorder of the tear film due to tear deficiency or excessive tear evaporation which causes damage to the exposed ocular surface and is associated with symptoms of ocular discomfort. If left untreated, severe dry eyes can lead to desiccation of the corneal epithelium, increased discomfort and sometimes loss of vision. Abundant evidence from animal models and clinical evaluations confirm that inflammation is an integral part of all moderate and severe Dry Eye Disease (DED) states and is likely to be significant in the pathogenesis leading to the chronicity of DED. Omega-3 essential fatty acids (EFAs) have been shown to have anti-inflammatory effects and inhibit multiple aspects of inflammatory response.

DED is a common and growing problem as our population ages, causing chronic pain and visual disturbance that is not adequately treated with current approaches. If left untreated, severe dry eyes can lead to desiccation of the corneal epithelium, increased discomfort and sometimes loss of vision.The benefits are the possibility of alleviating or eliminating these symptoms of DED and the clinical data that will be gained on the safety and efficacy of omega-3s, which are already being marketed over-the-counter for the treatment of DED without any hard scientific data. The potential benefits of treatment outweigh the minimal risk of participation.

This study hopes to discover more about the efficacy and tolerability of omega-3 EFA's in the treatment of dry eye and ocular surface disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Keratoconjunctivitis Sicca

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group

This group will receive Omega-3 EFA supplements for 8 weeks. They will take 4 capsules/day.

Group Type EXPERIMENTAL

Omega-3 Fatty Acid

Intervention Type DIETARY_SUPPLEMENT

Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:

* EPA (Eicosapentaenoic Acid) 1300mg
* DHA (Docosahexaenoic Acid) 900 mg
* Other Omega-3's 360mg
* Total Omega 3's 2560 mg

Placebo Group

This group will receive placebo supplements for 8 weeks. They will take 4 capsules a day.

Group Type PLACEBO_COMPARATOR

Soybean Soft Gels

Intervention Type DIETARY_SUPPLEMENT

Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omega-3 Fatty Acid

Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:

* EPA (Eicosapentaenoic Acid) 1300mg
* DHA (Docosahexaenoic Acid) 900 mg
* Other Omega-3's 360mg
* Total Omega 3's 2560 mg

Intervention Type DIETARY_SUPPLEMENT

Soybean Soft Gels

Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fish Oil Soft Gels ProOmega Placebo Soft Gels

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Each qualified participant will have an eye doctor's diagnosis of dry eye disease.
* Answers to both questions: "How often do your eyes feel dry, how often do your eyes feel irritated" will either be "Often or Constant." (Schaumberg)
* ≥ 18 years of age
* The current use of artificial tears at least one time per week.
* Be willing/able to return for all study visits and to follow instructions from the study investigator and his/her staff.
* Stable dosage for one month time of all ocular medications and systemic medications (includes Restasis).
* Be able to swallow large, soft gels.

Exclusion Criteria

* Patients who are allergic to ingredients of the treatment or placebo soft gels (fish, soybean oil, citrus).
* Current diagnosis of ocular infection (e.g. bacterial, viral or fungal).
* History of ocular herpetic keratitis.
* Past or current history of liver disease.
* Current use of blood thinners.
* Eye surgery (including cataract surgery) within 6 months prior to randomization.
* Previous LASIK surgery.
* Pregnant or nursing/lactating.
* Participation in a study of an investigational drug or device within the past 30 days.
* Cognitive or psychiatric deficit that precludes informed consent or ability to perform requirements of the investigation.
* Changes in ocular or systemic medications in the past 30 days.
* Contact lens wearers.
* Glaucoma diagnosis and/or use of glaucoma medications.
* Current use of punctual plugs.
* Current use of EPA/DHA supplements in excess of 1 gram/day.
* Use of ocular steroids currently or in the past 7 days.
* Patients planning on changing dosage of eye medications during the study.
* Patients who have an allergy to fluorescein.
* Patients who take aspirin daily.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No